[1]MATTHAYM A, ZEMANS R L, ZIMMERMAN G A, et al. Acute respiratory distress syndrome[J]. Nat Rev Dis Primers, 2019, 5(1): 18. DOI: 10.1038/s41572-019-0069-0.
[2]LIUQ M, CHU H Y, MA Y Y, et al. Salvianolic acid B attenuates experimental pulmonary fibrosis through inhibition of the TGF-β signaling pathway[J]. Sci Rep, 2016, 6: 27610. DOI: 10.1038/srep27610.
[3]HAMACHER J, LUCAS R, LIJNENH R, et al. Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2002, 166(5): 651-656. DOI: 10.1164/rccm.2109004.
[4]RAGHU G, COLLARDH R, EGAN J J, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183(6): 788-824. DOI: 10.1164/rccm.2009-040GL.
[5]MARSHALL R, BELLINGAN G, LAURENT G. The acute respiratory distress syndrome: fibrosis in the fast lane[J]. Thorax, 1998, 53(10): 815-817. DOI: 10.1136/thx.53.10.815.
[6]DHAINAUTJ F, CHARPENTIER J, CHICHE J D. Transforming growth factor-beta: a mediator of cell regulation in acute respiratory distress syndrome[J]. Crit Care Med, 2003, 31(4 Suppl): S258-S264. DOI: 10.1097/01.CCM.0000057901.92381.75.
[7]MAN S, SANCHEZ DUFFHUES G, TEN DIJKE P, et al. The therapeutic potential of targeting the endothelial-to-mesenchymal transition[J]. Angiogenesis, 2019, 22(1): 3-13. DOI: 10.1007/s10456-018-9639-0.
[8]MAK X, LI C L, XU J B, et al. LncRNA Gm16410 regulates PM 2.5-induced lung endothelial-mesenchymal transition via the TGF-β1/Smad3/p-Smad3 pathway[J]. Ecotoxicol Environ Saf, 2020, 205: 111327. DOI: 10.1016/j.ecoenv.2020.111327.
[9]SUZUKI T, TADA Y J, NISHIMURA R, et al. Endothelial-to-mesenchymal transition in lipopolysaccharide-induced acute lung injury drives a progenitor cell-like phenotype[J]. Am J Physiol Lung Cell Mol Physiol, 2016, 310(11): L1185-L1198. DOI: 10.1152/ajplung.00074.2016.
[10]TANG Y, CHENY L, CHU Z, et al. Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice[J]. Eur J Pharmacol, 2014, 723: 494-500. DOI: 10.1016/j.ejphar.2013.10.019.
[11]ZHANG Q Y, GAN C L, LIU H Y, et al. Cryptotanshinone reverses the epithelial-mesenchymal transformation process and attenuates bleomycin-induced pulmonary fibrosis[J]. Phytother Res, 2020, 34(10): 2685-2696. DOI: 10.1002/ptr.6699.
[12]ZHAO J L, PATEL J, KAUR S, et al. Sox9 and Rbpj differentially regulate endothelial to mesenchymal transition and wound scarring in murine endovascular progenitors[J]. Nat Commun, 2021, 12(1): 2564. DOI: 10.1038/s41467-021-22717-9.
[13]LIU D, ZENGB X, ZHANG S H, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats[J]. Crit Care Med, 2005, 33(10): 2309-2316. DOI: 10.1097/01.ccm.0000183161.81503.7d.
[14]ASHCROFT T, SIMPSONJ M, TIMBRELL V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale[J]. J Clin Pathol, 1988, 41(4): 467-470. DOI: 10.1136/jcp.41.4.467.
[15]BONAVENTURA A, VECCHI A, DAGNA L, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19[J]. Nat Rev Immunol, 2021, 21(5): 319-329. DOI: 10.1038/s41577-021-00536-9.
[16]GEORGEP M, WELLS A U, JENKINS R G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy[J]. Lancet Respir Med, 2020, 8(8): 807-815. DOI: 10.1016/S2213-2600(20)30225-3.
[17]BURNHAME L, JANSSEN W J, RICHES D W H, et al. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance[J]. Eur Respir J, 2014, 43(1): 276-285. DOI: 10.1183/09031936.00196412.
[18]LI J, ZHENG Y, LI M X, et al. Tanshinone IIA alleviates lipopolysaccharide-induced acute lung injury by downregulating TRPM7 and pro-inflammatory factors[J]. J Cell Mol Med, 2018, 22(1): 646-654. DOI: 10.1111/jcmm.13350.